drugset / Trial / NCT01113385

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

NCT01113385

NaSingle-groupOpen-labelTreatment

Summary

Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD). The purpose of this study is to investigate oral galactose as a benign treatment for FSGS in children. The investigators hypothesize that galactose, a simple milk sugar thought to bind to the protein factor (FSPF) that causes FSGS thereby inactivating it and stopping it from damaging the kidney, resulting in a reduction in glomerular permeability to albumin and decrease in proteinuria in children with nephrotic syndrome secondary to FSGS.

Timeline

Start
2009-10
Primary completion
2013-03
Completion
2013-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Galactose Diagnostic / imaging agent 0.2 g/kg Oral